… Interestingly, combination of sorafenib plus gefitinib, another EGFR inhibitor, shows a similar
PK pattern. Erlotinib and gefitinib share the same structural backbone and are metabolized …

… in clinical trials and real-world evidence. Afatinib was more effective as a first-line
treatment than gefitinib or erlotinib for elderly patients with EGFR-mutated advanced NSCLC. …

… head phase III randomized controlled trial is comparing … randomized controlled trial of ER
versus GE for advanced NSCLC with EGFR mutations. A total of 256 patients were randomized …

… (clinical trial ID: UMIN000017069), a randomized Phase III study comparing erlotinib plus
bevacizumab with erlotinib … versus gefitinib or erlotinib monotherapy in the Phase III FLAURA …

… inhibitors (TKIs) gefitinib and erlotinib have shown clear … However, none of these studies
were able to demonstrate an … in a randomized, direct comparison of gefitinib and erlotinib. …

… failure of erlotinib or gefitinib. However, in clinical trials, afatinib conferred only modest
response rates in this setting [18], [19]. Nevertheless, afatinib-based combinations warrant …

… randomized controlled trials (RCTs) that compared effectiveness between combined inhibition
therapy and control … The oral EGFR tyrosine kinase inhibitor (TKI), erlotinib, is approved by …

… We reviewed publications identified for head-to-head clinical trials on … trial, which compared
afatinib with gefitinib, and a phase 3 randomised controlled study of erlotinib versus gefitinib …

… Nevertheless, clinical trials of erlotinib have shown that some patients experience hepatotoxicity,
including ~3 % to 8 % with elevation of serum aminotransferase levels of grade 3 or 4 (…

… The first randomised clinical study which compared the anti-EGFR therapy with chemotherapy,
also in the sub-group of patients with tumours with an EGFR mutation present, was IPASS …